REVELATION BIOSCIENCES, INC. — fact timeline

REVELATION BIOSCIENCES, INC. reported three months ended March 31, 2026 results: net income $3.0 million, or $2.71 basic and diluted net loss per share.

“31, 2026 was $3.2 million compared to net cash used for operating activities of $2.8 million for the same period in 2025. Net loss for the three months ended March 31, 2026 was $3.0 million, or $2.71 basic and diluted net loss per share compared to net loss of $2.1 million, or $25.34 basic and diluted net loss per share for the three months ended March 31, 2025.”

REVELATION BIOSCIENCES, INC. issued warrant to Class J Common Stock warrant holders.

“Pursuant to the terms of the Class J Common Stock Warrants, the expiration date of such warrants is five years from the date of stockholder approval; accordingly, following stockholder approval on March 18, 2026, the expiration date of the warrants is March 18, 2031.”

REVELATION BIOSCIENCES, INC. issued 17,089,998 pre-split (4,272,500 post-split) new common stock warrants of warrant to two holders for aggregate gross proceeds of approximately $7.3 million from the exercise of Existing Warrants.

“new common stock warrants (the “Class J Common Stock Warrants”) as described below. The aggregate gross proceeds from the exercise of the Existing Warrants is approximately $7.3 million, before deducting financial advisory fees. The issuance of the Class J Common Stock Warrants was structured as an at-market transaction under Nasdaq rules. The Company intends to”

REVELATION BIOSCIENCES, INC. entered into Inducement Letters with two holders valued at approximately $7.3 million (effective 2026-01-23).

“On January 23, 2026, Revelation Biosciences, Inc. (the “Company”) entered into warrant exercise inducement offer letters (the “Inducement Letters”) with two holders”

REVELATION BIOSCIENCES, INC. issued 13,065,000 new common stock warrants (the "Class I Common Stock Warrants") of warrant to certain holders of existing Class H Common Stock Warrants for exercise of Existing Warrants at $2.20 per share for aggregate gross proceeds of approximately $9.6 million.

“On September 10, 2025, Revelation Biosciences, Inc. (the “Company”) entered into warrant exercise inducement offer letters (the “Inducement Letters”) with certain holders (the “Holders”) of 13,065,000 existing Class H Common Stock Warrants exercisable for an aggregate of 4,355,000 shares of its common stock (collectively, the “Existing Warrants”), to exercise their warrants at an exercise price of $2.20 per share, in exchange for the Company’s agreement to issue 13,065,000 new common stock warrants (the “Class I Common Stock Warrants”) as described below.”

REVELATION BIOSCIENCES, INC.: Filed Certificate of Amendment to effect a 1-for-3 reverse stock split (effective 2025-07-07).

“the Company filed a Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) effective on July 7, 2025, which effected a 1-for-3 reverse stock split as of 12:01 a.m. Eastern Standard Time on July 7, 2025”

George Tidmarsh resigned as Director at REVELATION BIOSCIENCES, INC..

“On May 23, 2025, George Tidmarsh, M.D., Ph.D., resigned from the Board of Directors of Revelation Biosciences, Inc. (the “Company”).”

REVELATION BIOSCIENCES, INC.: Certificate of Amendment to Third Amended and Restated Certificate of Incorporation filed to effect a 1-for-16 reverse stock split (effective 2025-01-28).

“the Company filed a Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) effective on January 28, 2025, which effected a 1-for-16 reverse stock split as of 12:01 a.m. Eastern Standard Time on January 28, 2025”

REVELATION BIOSCIENCES, INC. received a nasdaq compliance regained notice regarding stockholders equity (rules 5550(b)(1)).

“January 3, 2025, Revelation Biosciences, Inc. (the “Company”) received a decision letter issued by the Nasdaq Hearings Panel granting the Company’s request to continue its listing on The Nasdaq Stock Market, subject to e”

REVELATION BIOSCIENCES, INC. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

“January 3, 2025, Revelation Biosciences, Inc. (the “Company”) received a decision letter issued by the Nasdaq Hearings Panel granting the Company’s request to continue its listing on The Nasdaq Stock Market, subject to e”

REVELATION BIOSCIENCES, INC. shareholders approved Ratification of Baker Tilly US, LLP as auditor for fiscal year ending December 31, 2024 at the 2024-12-31 meeting.

“Stockholders ratified Baker Tilly US, LLP to audit our financial statements for the fiscal year ending December 31, 2024, based on the votes listed below: For Against Abstain 595,879 18,558 258 There were no broker non-votes regarding this proposal.”

REVELATION BIOSCIENCES, INC. shareholders approved Approval to increase the number of shares reserved under the Company's 2021 Equity Incentive Plan from 21,623 to 163,294.

“Stockholders approved an amendment to the 2021 Equity Incentive Plan to increase the number of shares reserved under the 2021 Equity Incentive Plan from 21,623 to 163,294, based on the votes listed below: For Against Abstain 107,447 42,981 2,729 There were 461,538 broker non-votes regarding this proposal.”

REVELATION BIOSCIENCES, INC. shareholders approved Election of two nominees for Class B director: James Rolke and Jess Roper.

“Stockholders approved to elect the two nominees for Class B director named herein to serve until the 2027 Annual Meeting or their successors are duly elected and qualified, based on the votes listed below: Director Nominee For Against Abstain James Rolke 122,822 23,715 6,620 Jess Roper 122,543 27,978 2,636 There were 461,538 broker non-votes regarding the election of directors.”

REVELATION BIOSCIENCES, INC. reported the three months ended March 31, 2024 results: net income $2.7 million, EPS $2.46 basic and diluted net loss per share.

“Revelation’s net loss for the three months ended March 31, 2024 was $2.7 million, or $2.46 basic and diluted net loss per share”

REVELATION BIOSCIENCES, INC. reported twelve months ended December 31, 2023 results: net income net loss of $0.1 million, EPS $0.53 basic and diluted net loss per share.

“Revelation’s net loss for the three and twelve months ended December 31, 2023 was $2.2 million and $0.1 million, or $8.33 and $0.53 basic and diluted net loss per share, respectively”

REVELATION BIOSCIENCES, INC. reported three months ended December 31, 2023 results: net income net loss of $2.2 million, EPS $8.33 basic and diluted net loss per share.

“Revelation’s net loss for the three and twelve months ended December 31, 2023 was $2.2 million and $0.1 million, or $8.33 and $0.53 basic and diluted net loss per share, respectively”

REVELATION BIOSCIENCES, INC. entered into Purchase Agreement with certain purchasers valued at gross proceeds of approximately $6.2 million (effective 2024-02-01).

“On February 1, 2024, Revelation Biosciences, Inc., (the “Company”), entered into a placement agency agreement (the “Placement Agency Agreement”) with Roth Capital Partners, LLC (the “Placement Agent”) and a securities purchase agreement (the “Purchase Agreement”) with certain purchasers for the purchase and sale, in a registered public offering by the Company (the “Public Offering”), of (i) 128,470 shares of its common stock, par value $0.001 per share (the “Common Stock”) and pre-funded warrants to purchase 1,236,530 shares of Common Stock (the “Pre-Funded Warrants”) and (ii) accompanying two warrants to purchase 2,730,000 shares of Common Stock (the “Class D Common Stock Warrants”) at a combined offering price of $4.53 per share of Common Stock and associated two Class D Common Stock Warrants, or $4.5299 per Pre-Funded Warrant and associated two Class D Common Stock Warrants, resulting”

REVELATION BIOSCIENCES, INC. entered into Placement Agency Agreement with Roth Capital Partners, LLC valued at gross proceeds of approximately $6.2 million (effective 2024-02-01).

“On February 1, 2024, Revelation Biosciences, Inc., (the “Company”), entered into a placement agency agreement (the “Placement Agency Agreement”) with Roth Capital Partners, LLC (the “Placement Agent”)”

REVELATION BIOSCIENCES, INC.: Filed Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation to effect a 1-for-30 reverse stock split, effective January 25, 2024 (effective 2024-01-25).

“On January 22, 2024, the Company filed a Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) effecting a reverse stock split as of 12:01 a.m. Eastern Standard Time on January 25, 2024 with a ratio of 1-for-30 (the “Reverse Split”).”

REVELATION BIOSCIENCES, INC. shareholders approved Approve adjournment of the Special Meeting to the extent there are insufficient proxies to approve the Reverse Stock Split at the 2024-01-17 meeting.

“Stockholders approved of the adjournment of the Special Meeting to the extent there are insufficient proxies at the Special Meeting to approve the Reverse Stock Split, based on the votes listed below: For Against Abstain 1,676,035 551,758 16,255”

REVELATION BIOSCIENCES, INC. shareholders approved Approve grant of discretionary authority to board of directors to effect a reverse stock split at a ratio within a range of one-for-2 to one-for-50 at the 2024-01-17 meeting.

“Stockholders approved the board of directors to effect a Reverse Stock Split of the outstanding shares of our common stock within one (1) year of January 17, 2024, at a specific ratio within a range of one-for-2 to a maximum of a one-for-50 split, with the specific ratio to be fixed within this range by the board of directors in its sole discretion without further stockholder approval, based on the votes listed below: For Against Abstain 1,410,313 831,173 2,562”

REVELATION BIOSCIENCES, INC. reported three and nine months ended September 30, 2023 results: net income $2.6 million, or $0.42 basic and diluted net loss per share.

“Revelation’s net loss for the three months ended September 30, 2023 was $2.6 million, or $0.42 basic and diluted net loss per share, compared to a net loss of $1.2 million, or $1.91 basic and diluted net loss per share for the same period in 2022.”

Lakhmir Chawla was elected as Director at REVELATION BIOSCIENCES, INC..

“On September 27, 2023, the Board of Directors elected Lakhmir Chawla M.D. (age 53) to the Board of Directors, as a Class C Director to fill the vacancy created by the resignation of Dr. La Belle.”

Curt LaBelle resigned as Director at REVELATION BIOSCIENCES, INC..

“On September 27, 2023, Curt LaBelle, M.D., resigned from the Board of Directors of Revelation Biosciences, Inc. (the "Company").”

REVELATION BIOSCIENCES, INC. reported the three and six months ended June 30, 2023 results: net income net loss of $1.4 million, or $0.25 basic and diluted net loss per share, EPS $0.25 basic and diluted net loss per share.

“On August 11, 2023, Revelation Biosciences, Inc. issued a press release announcing its financial results for the three and six months ended June 30, 2023.”

REVELATION BIOSCIENCES, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“August 8, 2023, Revelation Biosciences, Inc. (the “Company”) received a letter from the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company of its noncompliance with Nasdaq Listing Rule 5550(a)(2) (the “Rule”) by failing to maintain a minimum bid price for its common stock of at least $1.00 per share for 30 consecutive business days. According to the letter, the Company has a 180 calendar day grace period to regain compliance with the Rule (the “Grace Period”), subject to a potential 180 calendar day extension, as described below. To regain compliance, the Company’s common stock must have”

REVELATION BIOSCIENCES, INC. shareholders approved Ratification of the Auditor at the 2023-12-31 meeting.

“Stockholders approved Baker Tilly US, LLP to audit our financial statements for the fiscal year ending December 31, 2023, based on the votes listed below: For Against Abstain 1,981,630 26,027 301,657”

REVELATION BIOSCIENCES, INC. shareholders approved Approval of to increase he number of shares reserved under the Company’s 2021 Equity Incentive Plan.

“Stockholders approved an amendment to the 2021 Equity Incentive Plan to increase the number of shares reserved under the Plan from 68,288 to 648,678, based on the votes listed below: For Against Abstain 1,124,336 224,337 15,961”

REVELATION BIOSCIENCES, INC. shareholders approved Election of Directors.

“Stockholders approved to elect the two nominees for Class A director named herein to serve until the 2026 Annual Meeting or their successors are duly elected and qualified., based on the votes listed below: Director Nominee For Against Abstain Jennifer Carver 1,281,109 68,257 15,268 Curt LaBelle 1,280,290 66,949 17,395”

REVELATION BIOSCIENCES, INC.: Amended quorum requirement for stockholder meetings from majority to one-third of outstanding shares (effective 2023-07-06).

“On July 6, 2023, the Board of Directors of Revelation Biosciences, Inc. (the “Company”) approved an amendment to the Company’s Second Amended and Restated Bylaws (the “Bylaws”), effective immediately. The amendment modified the provisions for determining the presence of a quorum at all meetings of stockholders to provide that the presence, in person or by proxy, of the holders of at least one-third of all issued and outstanding shares of common stock entitled to vote at the meeting will constitute a quorum at all meetings of the stockholders for the transaction of business.”

REVELATION BIOSCIENCES, INC. reported three months ended March 31, 2023 results: net income $6.2 million, EPS $2.79 basic earnings per share and $1.96 diluted earnings per share.

“Revelation Biosciences Inc. Announces Financial Results for the Three Months Ended March 31, 2023 and Recent Corporate Progress”

REVELATION BIOSCIENCES, INC. reported twelve months ended December 31, 2022 results: net income $10.8 million, EPS $20.09 per share.

“Revelation’s net loss for the three and twelve months ended December 31, 2022 was $1.2 million and $10.8 million, or $1.77 per share and $20.09 per share, respectively”

REVELATION BIOSCIENCES, INC. reported three months ended December 31, 2022 results: net income $1.2 million, EPS $1.77 per share.

“Revelation’s net loss for the three and twelve months ended December 31, 2022 was $1.2 million and $10.8 million, or $1.77 per share and $20.09 per share, respectively”

REVELATION BIOSCIENCES, INC. entered into Purchase Agreement with certain purchasers valued at gross proceeds of approximately $15.6 million (effective 2023-02-09).

“a securities purchase agreement (the “Purchase Agreement”) with certain purchasers for the purchase and sale, in a registered public offering by the Company (the “Public Offering”), of (i) an aggregate of 2,888,600 shares of its common stock”

REVELATION BIOSCIENCES, INC. entered into Placement Agency Agreement with Roth Capital Partners, LLC valued at gross proceeds of approximately $15.6 million (effective 2023-02-09).

“On February 9, 2023, Revelation Biosciences, Inc., (the “Company”), entered into a placement agency agreement (the “Placement Agency Agreement”) with Roth Capital Partners, LLC (the “Placement Agent”)”

REVELATION BIOSCIENCES, INC.: Amended certificate of incorporation to increase authorized common shares from 100,000,000 to 500,000,000 and effect a 1-for-35 reverse stock split (effective 2023-02-01).

“On January 30, 2023, the Company filed a Certificate of Amendment of Third Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) reflecting the change in authorized shares of common stock from 100,000,000 to 500,000,000 and effecting a reverse stock split as of 12:01 a.m. Eastern Standard Time on February 1, 2023 with a ratio of 1-for-35”

REVELATION BIOSCIENCES, INC. shareholders approved Ratification of the Auditor at the 2023-12-31 meeting.

“Proposal 3 – Ratification of the Auditor Stockholders approved Baker Tilly US, LLP to audit our financial statements for the fiscal year ending December 31, 2023, based on the votes listed below: For Against Abstain 12,219,710 274,018 584,110”

REVELATION BIOSCIENCES, INC. shareholders approved Reverse Stock Split at the 2023-01-30 meeting.

“Proposal 2 – Reverse Stock Split Stockholders approved the board of directors to effect a Reverse Stock Split of the outstanding shares of our common stock within one (1) year of January 30, 2023, at a specific ratio within a range of one-for-twenty (1-for-20) to a maximum of a one-for-one hundred (1-for-100) split, with the specific ratio to be fixed within this range by the board of directors in its sole discretion without further stockholder approval, based on the votes listed below: For Against Abstain 56,353,405 3,599,118 3,125,315”

REVELATION BIOSCIENCES, INC. shareholders approved Increase in the Number of Shares of Authorized Common Stock.

“Proposal 1 – Increase in the Number of Shares of Authorized Common Stock Stockholders approved the amendment to increase the number of authorized common stock from 100,000,000 to 500,000,000 shares, based on the votes listed below: For Against Abstain 53,329,345 6,506,571 3,241,922”

REVELATION BIOSCIENCES, INC.: Filed certificate of designation creating a new series of Preferred Stock with designated voting rights, redemption provisions, and other preferences, effective upon filing (effective 2022-12-19).

“On December 19, 2022, the Company filed a certificate of designation (the “Certificate of Designation”) with the Secretary of State of Delaware, effective as of the time of filing, designating the rights, preferences, privileges and restrictions of the share of Preferred Stock.”

REVELATION BIOSCIENCES, INC. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“December 6, 2022, Revelation Biosciences, Inc. (the “Company”) received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), notifying the Company that it was not in compliance with Nasdaq Listing Rule 5550(a)(2) (the “Rule”) which requires listed companies to maintain a minimum bid price of $1.00 per share. Under Nasdaq Listing Rule 5810(c)(3)(A), the Company had been granted a period of 180 calendar days to regain compliance with the minimum bid price requirement. Upon the expiration of that grace period, on December 5, 2022, the Company rece”

REVELATION BIOSCIENCES, INC. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).

“While the Company did complete a $5 million offering in July 2022, in the Form 10-Q for the quarter ended September 30,2022 the Company reported a stockholders’ equity of $2,227,768, less than the Stockholders’ Equity Requirement. As a result, on November 23, 2022, the Company received a further deficiency letter (the “Second Nasdaq Letter”). The Second Nasdaq”

REVELATION BIOSCIENCES, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“Equity Requirement was based on the Company’s filing of its Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, reporting the stockholders’ deficit of $98,511. Pursuant to the First Nasdaq Letter, the Company submitted a plan to regain compliance and the Company which contemplated capital raises of $10 million, following which Nasdaq”

REVELATION BIOSCIENCES, INC. reported the nine months ended September 30, 2022 results: net income $9.6 million, EPS $0.57 per share.

“Revelation’s net loss for the three and nine months ended September 30, 2022 was $1.2 million and $9.6 million, or $0.06 per share and $0.57 per share, respectively”

REVELATION BIOSCIENCES, INC. reported the three months ended September 30, 2022 results: net income $1.2 million, EPS $0.06 per share.

“Revelation’s net loss for the three and nine months ended September 30, 2022 was $1.2 million and $9.6 million, or $0.06 per share and $0.57 per share, respectively”

Sean Fitzpatrick departed as Executive Officer at REVELATION BIOSCIENCES, INC..

“Andreas Typaldos and Sean Fitzpatrick ceased serving as executive officers of Petra”

Andreas Typaldos departed as Executive Officer at REVELATION BIOSCIENCES, INC..

“Andreas Typaldos and Sean Fitzpatrick ceased serving as executive officers of Petra”

William Carson departed as Director at REVELATION BIOSCIENCES, INC..

“each of Andreas Typaldos, David Dobkin, Anthony Hayes, Robert Nicholson, Barry Dennis and William Carson ceased serving as a director of Petra”

Barry Dennis departed as Director at REVELATION BIOSCIENCES, INC..

“each of Andreas Typaldos, David Dobkin, Anthony Hayes, Robert Nicholson, Barry Dennis and William Carson ceased serving as a director of Petra”

Robert Nicholson departed as Director at REVELATION BIOSCIENCES, INC..

“each of Andreas Typaldos, David Dobkin, Anthony Hayes, Robert Nicholson, Barry Dennis and William Carson ceased serving as a director of Petra”